A new study suggests that a blood-based protein signature may help identify people at risk of developing lung cancer more accurately than traditional screening criteria alone. The results are promising because they point to a future in which lung cancer screening can be better targeted, but they also raise important questions about validation, access, and how these tools can be used in real-world medicine.
Modern condition The New York Times informs readers that researchers have identified a group of proteins that can predict lung cancer five years before symptoms appear and that an anti-inflammatory drug “could significantly reduce the risk of lung cancer in people with elevated concentrations of these proteins.”
This sounds too good to be true. Is it so?
Latent He studies It was published in the magazine “Cell”. It details the results of a complex, multifaceted research project from BioBank that provides researchers with new information about how lung cancer and lung carcinogenesis are driven by a combination of molecular changes resulting from smoking and lung inflammation. Although I am not qualified to evaluate whether the article’s conclusions about the molecular carcinogenicity of lung cancer are correct, I have repeatedly been disappointed by new claims that blood tests can detect cancer in its early stages before symptoms appear, but these claims have subsequently failed. Recently He studiesGrail’s Gallery test failed. Is cell study another example?
Experimental results
Most often, we determine a high risk of lung cancer based on clinical indicators, for example, the patient’s age, smoking history, family history, etc. The authors found no greater “predictability” in their “signature” of 14 proteins than clinical outcomes when each was considered individually; However, when combined, the information reinforces each other. This is reflected in the graph showing the area under the curve (AUC). [1] From both clinical model and blood test.
The AUC for the usual risk factors was 0.806, while the AUC when adding the protein signature increased to 0.865.
To put it more simply, using a protein signature improved the ability to predict future lung cancer by 5%, which is small, but even a little better is desirable when dealing with a highly lethal cancer.
The authors went on to discuss a clinical trial of an anti-inflammatory drug, canakinumab, an interleukin-1 beta inhibitor, which failed to reduce deaths from heart disease in the CANTOS trial. Canakinumab has been repurposed as a treatment for lung cancer, where it has been used again to fail. However, it has been observed that it is associated with a lower risk of lung cancer.
A re-examination of data from CANTOS indicates that the number of people in General population Who will need treatment (NNT) with canakinumab? Save a life It would be more than 1500. However, if the population examined were “enriched” to include only those with a clinical risk and protein signature, the NNT might improve to a level as low as 55. While no experimental chemotherapy has been effective in reducing the incidence of lung cancer, if canakinumab can be shown to reduce the incidence of lung cancer without significant drug-related morbidity, it may be indicated for this high-risk population and prevent many lung cancers.
Challenges in implementation
There are still multiple problems to be solved.
the Food and Drug Administration The website discloses that canakinumab is a strong immunosuppressant, which poses a known risk of reactivation or progression of tuberculosis and other serious infections. Hypersensitivity reactions, including anaphylaxis, have been reported. Importantly, mortality from infection was significantly higher in the CANTOS canakinumab group.
Neither the New York Times articles nor the article addressed the cost of protein testing or treatment with canakinumab. A commercial test for the 14-protein panel has not yet been developed. Based on the prices of currently available molecular tests for early detection of multiple cancers e.g exhibitionthe price will range from $750 to $1,000 before any sales.
Based on estimated With the cost of canakinumab, annual prophylaxis would cost more than $250,000 and would need to be continued for more than five years.
Ignoring concerns about cost and toxicity for now, could a randomized trial be completed for high-risk individuals? Most eligible patients will already be eligible for a low-dose CT scan. Would it be ethical to withhold this more sensitive test, which is recommended by guidelines and covered by both Medicare and private insurance, from high-risk patients in both treatment and control arms?
If CT scanning were incorporated into the research protocol, the number of research subjects required to reach statistical significance would have to be much larger, increasing the complexity and cost of the research.
Future trends
This study expands our investigation of whether, and to what extent, blood-based biomarkers may help improve lung cancer risk prediction beyond age and smoking history alone. Unfortunately, proof of concept has not yet been demonstrated. Reported improvement in discrimination suggests Molecular screening tools could one day help identify individuals at risk who might otherwise be missed. This is important because lung cancer outcomes depend heavily on early detection, and better risk stratification could make screening more accurate and more efficient.
However, these results should be viewed as encouraging and not definitive. Improving the AUC is useful, but does not by itself prove that a test will reduce mortality, avoid unnecessary follow-up, or perform equally well across diverse populations and clinical settings. Before such an approach can be widely adopted, it will need external validation, future testing, cost-effectiveness analysis, and careful assessment of false positives, false negatives, and eventual harms.
Ideally, biomarkers would not replace clinical judgment or current screening programmes, but rather would enhance them. If validated, protein-based risk models demonstrate their potential to improve outcomes, not just staging, and could help move lung cancer screening from an explicit eligibility framework to a more individualized and precise public health strategy. This is still a work in progress.
[1] The area under the curve (AUC) measures the ability to distinguish between two categories, in this case between those at low and high risk. 0.5 is essentially the discrimination of a coin toss; 1 is complete separation.
